Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) Director Jack L. Wyszomierski sold 7,535 shares of the stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $43.09, for a total value of $324,683.15. Following the completion of the transaction, the director now owns 358,882 shares in the company, valued at approximately $15,464,225.38. This represents a 2.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Exelixis Stock Performance
Shares of NASDAQ:EXEL opened at $43.03 on Friday. The company’s 50-day moving average is $39.03 and its 200 day moving average is $36.64. The company has a market capitalization of $11.73 billion, a P/E ratio of 24.31, a price-to-earnings-growth ratio of 1.13 and a beta of 0.28. Exelixis, Inc. has a fifty-two week low of $21.36 and a fifty-two week high of $48.85.
Hedge Funds Weigh In On Exelixis
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Tallon Kerry Patrick bought a new stake in Exelixis in the 4th quarter valued at about $2,619,000. Janney Montgomery Scott LLC raised its stake in Exelixis by 9.5% in the 4th quarter. Janney Montgomery Scott LLC now owns 33,296 shares of the biotechnology company’s stock valued at $1,109,000 after acquiring an additional 2,897 shares during the period. Chicago Partners Investment Group LLC bought a new stake in Exelixis in the 4th quarter valued at about $247,000. Spire Wealth Management raised its stake in Exelixis by 49.9% in the 4th quarter. Spire Wealth Management now owns 9,010 shares of the biotechnology company’s stock valued at $300,000 after acquiring an additional 3,000 shares during the period. Finally, Longboard Asset Management LP bought a new stake in Exelixis in the 4th quarter valued at about $245,000. 85.27% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on EXEL
About Exelixis
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Featured Articles
- Five stocks we like better than Exelixis
- How to trade penny stocks: A step-by-step guide
- A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- 3 Stocks Getting Rare Double Upgrades From Analysts
- How to Calculate Retirement Income: MarketBeat’s Calculator
- This Banking Giant Just Got a $90 Price Target Upgrade
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.